(RTTNews) - Capricor Therapeutics (CAPR) announced that its phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback